HS-10516 + Lenvatinib

Phase 2

Hansoh Pharmaceutical Group Co Limited/ADR (HNSPF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

HNSPFPhase 2$23.2B

HS-10516 + Lenvatinib Phase 2 Est. Readout

HS-10516 + Lenvatinib• Advanced Clear Cell Renal Cell Carcinoma104

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Advanced Clear Cell Renal Cell Carcinoma

View Full Landscape

Drug Information

Target Indication

Advanced Clear Cell Renal Cell Carcinoma

Clinical Trial

NCT07097935

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HNSPF

Hansoh Pharmaceutical Group Co Limited/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Flumatinib 600mg qdPhase 3

CML, CML-CP,MMR,TKI

AumolertinibPhase 3

Non-small Cell Lung Cancer

HS-20093Phase 3

Advanced Solid Tumor

HS-20089Phase 3

Ovarian Cancer

AlmonertinibPhase 3

Non-small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts